Curcuminoids C3 Complex® or placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months

Other Name: Curcuminoids C3 Complex® (Sabinsa Co.)

Eligibility

Ages Eligible for Study:

18 Years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

Yes

Criteria

Inclusion Criteria:

Age>18

A diagnosis for colon/rectal polyp resection, polypectomy

Subjects must be able to have the capacity and must be willing to provide informed consent

Premenopausal women must be surgically incapable of childbearing or be using a medically acceptable method of contraception (oral contraceptives, diaphragms, condoms with spermicide, IUD, progesterone injection or implant) throughout the entire length of the study

Men should wear condoms during the duration of the study given the unknown effects of curcumin on sperm viability, fertility

Active infection including viral, bacterial, atypical or fungal infections of any organ system including HIV

Previous history of allergy to turmeric, Indian curries, aspirin or NSAIDs

Pregnant or lactating women

Dementia or other neurologic or psychiatric disease which may impede the ability to follow the protocol

Inability to swallow pills

Prior or concurrent therapy with any herbal or dietary supplement containing curcuminoids

Concurrent use of anticoagulants or antiplatelets including warfarin, clopidogrel

Prior or concurrent use of colorectal cancer chemopreventive agents including herbals: Sulindac or other NSAIDs, aspirin, COX-2 inhibitors, 5-aminosalicylate, folate, calcium, or their use within 14 days of enrollment

Concurrent use of immunosuppressants

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00118989